Cusculine (Synonyms: FAC21) |
Katalog-Nr.GC79043
One-Click Copy Product Info
|
Cusculine (FAC21) is an oropouche virus (OROV) endonuclease inhibitor with an IC50 of 1.4 μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 143438-95-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vitro, Cusculine (FAC21) (72 h) exhibits low cytotoxicity in Vero cells (CC50 = 1640 μM)[1]. Cusculine (15.125-250 μM) potently inhibits OROV infection in Vero cells (EC50 = 33.03 μM)[1]. Cusculine (125 μM; 8-48 hpi) strongly inhibits OROV replication early in Vero cells (99.9% inhibition at 8 hpi)[1]. Cusculine (18.5 μM; 45 min) modestly interacts with dsRNA, showing partial intercalation activity[1]. Cusculine (0-90 μM; 10 min) potently inhibits OROV N-terminal endonuclease as a competitive inhibitor (IC50 = 1.4 μM)[1]. Cusculine stably binds to the active site of OROV N-terminal endonuclease, with favorable binding free energy and conserved interacting residues[1].
References:
[1]. Saivish MV, et al. Acridones as promising drug candidates against Oropouche virus. Curr Res Microb Sci. 2023;6:100217. Published 2023 Dec 23.
| Cas No. | 143438-95-3 | SDF | |
| Überlieferungen | FAC21 | ||
| Formula | C18H19NO6 | M.Wt | 345.35 |
| Löslichkeit | DMSO: 41.67 mg/mL (120.66 mM; Need ultrasonic) | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8956 mL | 14.4781 mL | 28.9561 mL |
| 5 mM | 579.1 μL | 2.8956 mL | 5.7912 mL |
| 10 mM | 289.6 μL | 1.4478 mL | 2.8956 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)